Overview of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis

G&H Which patients with metabolic dysfunction-associated steatohepatitis are at greatest risk of progressing to cirrhosis, and how often does this occur? MN The patients at greatest […]

Fibroblast Growth Factor 21 Agonists for the Treatment of Patients With Metabolic Dysfunction-Associated Steatohepatitis

G&H Why are fibroblast growth factor 21 agonists being studied for the treatment of metabolic dysfunction-associated steatohepatitis? PN Fibroblast growth factor 21 (FGF21) agonists are being […]

Exercise in Patients With Metabolic Dysfunction-Associated Steatohepatitis

G&H Has exercise been shown to improve liver fibrosis and histology without body weight loss in patients with metabolic dysfunction-associated steatohepatitis? JS At this point in […]

Recent Data From the ESSENCE Trial on Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

G&H What is the rationale for studying semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis? NA Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that […]

Overview of Lean MASH and MASLD

G&H How should lean metabolic dysfunction-associated steatohepatitis be defined? VW By definition, if someone is labeled as having lean metabolic dysfunction-associated steatohepatitis (MASH), 2 criteria should […]

Insights Into Combination Therapy for Metabolic Dysfunction-Associated Steatohepatitis

G&H What are the main reasons for using combination therapy for metabolic dysfunction-associated steatohepatitis? MC Given the current landscape of efficacy across the different agents that […]

Utilization of Noninvasive Tests to Diagnose At-Risk Metabolic Dysfunction-Associated Steatohepatitis

G&H Why is it important to diagnose at-risk metabolic dysfunction-associated steatohepatitis? MN Metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis) is prevalent in the United […]